Brandon Von Tobel

Dr. Brandon von Tobel joins Reglagene as a healthcare veteran with almost 20 years of executive experience at companies ranging from early-stage startups to publicly traded organizations. After foregoing a neurosurgery residency and based upon previous stints at McKinsey & Company, Morgan Stanley, Salomon Smith Barney, Merrill Lynch, and Innovation Philadelphia, Brandon joined the venture capital firm WFD Ventures, an evergreen healthcare fund focused on med-tech, healthcare IT, and medical devices. Brandon helped the WFD Ventures portfolio company ImaCor Inc. achieve FDA clearance for its hTEE ultrasound probe and secured a $25MM investment led by Johnson & Johnson Development Corporation (JJDC) based upon his go-to-market commercialization strategy. Brandon subsequently joined ImaCor Inc. as its operational and financial executive and helped build it from a pre-revenue startup into a global critical care brand, ultimately running its west coast sales team, leading international distribution, and becoming the company’s CFO and President. After the private equity acquisition of ImaCor, Brandon joined Cadit Health as its CFO/COO to help this healthcare IT Zocdoc competitor grow and diversify its call center-based business model into lucrative pharmaceutical company partnerships. While negotiating the sale of Cadit Health, Brandon launched the family office advisory firm D-Ink Inc. to continue his passion to build and fund healthcare solutions. Throughout his career, Brandon has built and sold businesses worth almost a billion dollars and raised over $375 million in capital in order to accomplish those goals. Brandon is a magna cum laude graduate of Columbia University where he received a BA in premedical studies with concentrations in French, Biology, and Economics; he received a master’s degree in Bioethics from The University of Pennsylvania School of Medicine; and he received his medical doctorate on a trustee scholarship from The University of Miami School of Medicine. He is a Venture Partner at the Cancer Fund.